|
|
|
|
| LEADER |
01858nam a2200373 u 4500 |
| 001 |
EB001865509 |
| 003 |
EBX01000000000000001029589 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited)
|h Elektronische Ressource
|b indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features
|
| 246 |
3 |
1 |
|a Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation ocrelizumab (Ocrevus)
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, November 21, 2017
|
| 300 |
|
|
|a 1 PDF file (8 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / economics
|
| 653 |
|
|
|a Multiple Sclerosis, Relapsing-Remitting / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Immunologic Factors / therapeutic use
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / therapeutic use
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK534395
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features
|